HC Wainwright raises Elicio Therapeutics price target to $23

0 min read | Published on 15 Jun 2026, 06:57 PM |Updated on 15 Jun 2026, 06:57 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

HC Wainwright & Co. analyst Robert Burns maintained a Buy rating on Elicio Therapeutics and raised the price target to $23 from $17.

*this image is generated using AI for illustrative purposes only.

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Elicio Therapeutics and increased the price target to $23 from $17. The revised target reflects a more optimistic outlook on the company's stock performance.

Rating and Target Details

The decision to uphold the Buy rating accompanies a significant adjustment in the valuation expectations for Elicio Therapeutics. The new price target of $23 represents an increase over the previous target of $17.

Analyst	Firm	Rating	Previous Target	New Target
Robert Burns	HC Wainwright & Co.	Buy	$17	$23

What specific factors or developments drove the analyst's increased optimism for Elicio Therapeutics?

How might this revised price target influence investor sentiment and trading volume in the short term?

What upcoming milestones or data releases could further validate or challenge the new $23 price target?

B. Riley Securities initiates coverage on Elicio Therapeutics with Buy rating

0 min read | Published on 10 Jun 2026, 11:43 PM |Updated on 10 Jun 2026, 11:43 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

B. Riley Securities analyst Mayank Mamtani initiated coverage on Elicio Therapeutics with a Buy rating and a price target of $27, indicating a positive outlook on the stock.

*this image is generated using AI for illustrative purposes only.

B. Riley Securities analyst Mayank Mamtani has initiated coverage on Elicio Therapeutics with a Buy rating and a price target of $27. The rating reflects a positive outlook on the company's stock performance.

Coverage Details

The initiation of coverage by B. Riley Securities highlights the firm's confidence in Elicio Therapeutics. The Buy rating suggests that the stock is expected to outperform the market.

Price Target

The announced price target of $27 provides a specific valuation benchmark for investors. This target indicates the potential upside from the current trading levels.